Markers of oxidative stress in children with Down syndrome
-
Ingrid Žitňanová
Abstract
Background: Persons with Down syndrome have increased vulnerability to oxidative stress caused by overexpression of superoxide dismutase, an antioxidant enzyme coded on chromosome 21. Increased oxidative stress may lead to oxidative damage of important macromolecules. We monitored this damage by measuring levels of different biomarkers of oxidative stress (protein carbonyls and 4-hydroxy-2-nonenal), as well as plasma antioxidant capacity, in children with Down syndrome. A total of 20 children with Down syndrome and 18 healthy individuals were recruited for this purpose.
Methods: Plasma protein carbonyls were measured using an ELISA technique, 4-hydroxy-2-nonenal was monitored by HPLC and the antioxidant capacity was evaluated using a ferric reducing ability of plasma (FRAP) assay.
Results: We found that children with Down syndrome had significantly elevated levels of protein carbonyls compared to healthy controls (p<0.01). Levels of 4-hydroxy-2-nonenal and antioxidant capacity were similar in both groups.
Conclusion: Our results on oxidative damage to proteins confirm the assumption of increased oxidative stress in individuals with Down syndrome.
References
1. Sinet PM. Metabolism of oxygen derivatives in Down's syndrome. Ann NY Acad Sci 1982; 396:83–94.10.1111/j.1749-6632.1982.tb26845.xSuche in Google Scholar
2. Jenner P. Oxidative stress in Parkinson's disease and other neurodegenerative disorders. Pathol Biol 1996; 15:57.Suche in Google Scholar
3. DeHaan JB, Newman JD, Kola I. Cu/Zn superoxide dismutase mRNA and enzyme activity and susceptibility to lipid peroxidation, increases with aging in murine brains. Brain Res Mol Brain Res 1992; 13:179–87.10.1016/0169-328X(92)90025-7Suche in Google Scholar
4. Muchová J, Šustrová M, Garaiová I, Liptáková A, Blažíček P, Kvasnička P, et al. Influence of age on activities of antioxidant enzymes and lipid peroxidation products in erythrocytes and neutrophils of Down syndrome patients. Free Radic Biol Med 2001; 31:499–508.10.1016/S0891-5849(01)00609-8Suche in Google Scholar
5. Garaiová I, Muchová J, Šustrová M, Blažíček P, Sivoňová M, Kvasnička P, et al. The relationship between antioxidant systems and some markers of oxidative stress in persons with Down syndrome. Biologia 2004; 59:781–8.Suche in Google Scholar
6. Tan YH, Tischfield J, Ruddle FH. The linkage of genes for human interferon-induced antiviral protein and indophenol oxidase-B traits to chromosome G21. J Exp Med 1993; 137:317–30.10.1084/jem.137.2.317Suche in Google Scholar
7. Ďuračková Z, Korytár P, Sivońová M, Ursínyová M, Šustrová M. Does Cu/Zn-superoxide dismutase exhibit a nondismutase activity? Curr Top Biophys 2000; 24:39–43.Suche in Google Scholar
8. Žitňanová I, Korytár P, Aruoma OI, Šustrová M, Garaiová I, Muchová J, et al. Uric acid and allantoin levels in Down syndrome: antioxidant and oxidative stress mechanisms? Clin Chim Acta 2004; 341:139–46.10.1016/j.cccn.2003.11.020Suche in Google Scholar
9. Benzie F, Strain JJ. Ferric reducing ability of plasma (FRAP) as a measure of “antioxidant power”: the FRAP assay. Med Biochem 1996; 239:70–6.10.1006/abio.1996.0292Suche in Google Scholar
10. Buss H, Chan TP, Sluis KB, Domingan NM, Winterbourn CC. Protein carbonyl measurement by a sensitive ELISA method. Free Radic Biol Med 1997; 23:361–6.10.1016/S0891-5849(97)00104-4Suche in Google Scholar
11. Sitte N, Merker K, Grune T. Proteasome-dependent degradation of oxidized proteins in MRC-5 fibroblasts. FEBS Lett 1998; 440:399–402.10.1016/S0014-5793(98)01495-1Suche in Google Scholar
12. Kinter M. Quantitative analysis of 4-hydroxy-2-nonenal. In: Punchard NA, Kelly FJ, editors. Free radicals. A practical approach. Oxford: IRL Press, Oxford University Press, 1996.Suche in Google Scholar
13. Moreira PI, Smith MA, Zhu X, Nunomura A, Castellani RJ, Perry G. Oxidative stress and neurodegeneration. Ann NY Acad Sci 2005; 1043:545–52.10.1196/annals.1333.062Suche in Google Scholar
14. Zarkovic K. 4-Hydroxynonenal and neurodegenerative diseases. Mol Aspects Med 2003; 24:293–303.10.1016/S0098-2997(03)00024-4Suche in Google Scholar
15. Chapman ML, Rubin BR, Gracy RW. Increased carbonyl content of proteins in synovial fluid from patients with rheumatoid arthritis. J Rheumatol 1989; 16:15–9.Suche in Google Scholar
16. Smith CD, Carney JM, Starke-Reed PE, Oliver CN, Stadtman ER, Floyd RA. Excess brain protein oxidation and enzyme dysfunction in normal aging and in Alzheimer disease. Proc Natl Acad Sci USA 1991; 88:347–53.10.1073/pnas.88.23.10540Suche in Google Scholar
17. Gladstone IM, Levine RL. Oxidation of proteins in neonatal lungs. Pediatrics 1994; 93:764–8.10.1542/peds.93.5.764Suche in Google Scholar
18. Yoritaka A, Hattori N, Uchida K, Tanaka M, Stadtman ER, Mruno Y. Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease. Proc Natl Acad Sci USA 1996; 93:2696–701.10.1073/pnas.93.7.2696Suche in Google Scholar
19. Uchida K, Toyokuni S, Kishikawa S, Oda H, Hiaia H, Stadtman ER. Michael addition-type 4-hydroxy-2-nonenal adducts in modified low-density lipoproteins: markers for atherosclerosis. Biochemistry 1994; 33:12487–94.10.1021/bi00207a016Suche in Google Scholar
20. Balcz B, Kirchner L, Cairns N, Fountoulakis M, Lubec G. Increased brain protein levels of carbonyl reductase and alcohol dehydrogenase in Down syndrome and Alzheimer's disease. J Neural Transm 2001; 16(Suppl):193–201.10.1007/978-3-7091-6262-0_15Suche in Google Scholar
21. Odetti P, Angelini G, Dapino D, Zaccheo D, Garibaldi S, Dagna-Bricarelli F, et al. Early glycoxidation damage in brains from Down's syndrome. Biochem Biophys Res Commun 1998; 243:849–51.10.1006/bbrc.1998.8186Suche in Google Scholar
22. Ďuračková Z, Šustrová M, Korytár P, Muchová J, Garaiová I, Liptáková A. What is the real function of Cu/Zn-superoxide dismutase? Free Radic Biol Med 2000;29(Suppl):abstract 29 (Proceedings of the 7th Annual Meeting of the Oxygen Society).Suche in Google Scholar
23. Ciechanover A, Orian A, Schwartz AL. The ubiquitin-mediated proteolytic pathway. Mode of action and clinical implications. J Cell Biochem 2000; 34(Suppl):4051.10.1002/(SICI)1097-4644(2000)77:34+<40::AID-JCB9>3.0.CO;2-6Suche in Google Scholar
24. Stadtman ER. Protein oxidation and aging. Science 1992; 257:1220–4.10.1126/science.1355616Suche in Google Scholar
25. Dean RT, Armstrong S, Fu S, Jessup W. Oxidized proteins and their enzymatic proteolysis in eukaryotic cells: a critical appraisal. In: Nohl H, Esterbauer H, Rice-Evans C, editors. Free radicals in the environment, medicine and toxicology. London: Richelieu Press, 1994:47–79.Suche in Google Scholar
26. Friguet B, Szweda LI. Inhibition of the multicatalytic proteinase (proteasome) by 4-hydroxy-2-nonenal cross-linked protein. FEBS Lett 1997; 405:21–5.10.1016/S0014-5793(97)00148-8Suche in Google Scholar
27. Sitte N, Merker K, von Zglinicki T, Grune T. Protein oxidation and degradation during proliferative senescence of human MRC-5 fibroblasts. Free Radic Biol Med 2000; 28:701–8.10.1016/S0891-5849(99)00279-8Suche in Google Scholar
28. Hoff HF, O'Neil J, Chisolm GM III, Cole TB, Quehenberger O, Esterbauer H, et al. Modification of low density lipoprotein with 4-hydroxynonenal induces uptake by macrophages. Arteriosclerosis 1989; 9:538–49.10.1161/01.ATV.9.4.538Suche in Google Scholar
29. Kinter M, Robinson CS, Grimminger LC, Gillies PJ, Shimshick EJ, Ayers C. Whole blood and plasma concentrations of 4-hydroxy-2-nonenal in Watanabe heritable hyperlipidemic versus New Zealand White rabbits. Biochem Biophys Res Commun 1994; 199:671–5.10.1006/bbrc.1994.1280Suche in Google Scholar
30. Sullivan SJ, Roberts RJ, Spitz DR. Replacement of media in cell culture alters oxygen toxicity: possible role of lipid aldehydes and glutathione transferase in oxygen toxicity. J Cell Physiol 1991; 147:427–33.10.1002/jcp.1041470307Suche in Google Scholar
31. Srivastava S, Chandra A, Wang LF, Seifert WEJR, Dague BB, Ansari NH, et al. Metabolism of the lipid peroxidation product 4-hydroxy-trans-2-nonenal in isolated perfused rat heart. J Biol Chem 1998; 273:10893–900.10.1074/jbc.273.18.10893Suche in Google Scholar
32. Parola M, Bellomo G, Robino G, Barrera G, Dianzani MU. 4-Hydroxynonenal as a biological signal: molecular basis and pathophysiological implications. Antioxid Redox Signal 1999; 1:255–84.10.1089/ars.1999.1.3-255Suche in Google Scholar
33. Hartley DP, Ruth JA, Petersen DR. The hepatocellular metabolism of 4-hydroxynonenal by alcohol dehydrogenase, aldehyde dehydrogenase and glutathione-S-transferases. Arch Biochem Biophys 1995; 316:197–205.10.1006/abbi.1995.1028Suche in Google Scholar
34. Uchida K, Stadtman ER. Quantitation of 4-hydroxynonenal protein adducts. Methods Enzymol 1994; 233:371–80.10.1016/S0076-6879(94)33043-3Suche in Google Scholar
35. Horáková E, Ondrejičková O, Vajdová M, Korytár P, Ďuračková Z, Schaur RJ. Mechanisms of iron-induced oxidative modifications of creatine kinase in rat brain in vitro. Possible involvement of HNE. Gen Physiol Biophys 2002; 21:327–36.Suche in Google Scholar
36. Pratico D, Iuliano L, Amerio G, Tang LX, Rokach J, Sabatino G, et al. Down's syndrome is associated with increased 8,12-iso-iPF2alpha-VI levels: evidence for enhanced lipid peroxidation in vivo. Ann Neurol 2000; 48:795–8.10.1002/1531-8249(200011)48:5<795::AID-ANA15>3.0.CO;2-#Suche in Google Scholar
37. Jovanovic SV, Clements D, MacLeod K. Biomarkers of oxidative stress are significantly elevated in Down syndrome. Free Radic Biol Med 1998; 25:1044–8.10.1016/S0891-5849(98)00137-3Suche in Google Scholar
38. Carratelli M, Porcaro L, Ruscica M, De Simone E, Bertelli AA, Corsi MM. Reactive oxygen metabolites and prooxidant status in children with Down's syndrome. Int J Clin Pharmacol Res 2001; 21:79–84.Suche in Google Scholar
©2006 by Walter de Gruyter Berlin New York
Artikel in diesem Heft
- Recent advances in physiological calcium homeostasis
- Associations of apolipoprotein E exon 4 and lipoprotein lipase S447X polymorphisms with acute ischemic stroke and myocardial infarction
- Association of angiotensin II type 1 receptor gene polymorphism with carotid atherosclerosis
- Comparison of the TaqMan and LightCycler systems in pharmacogenetic testing: evaluation of CYP2C9*2/*3 polymorphisms
- Urinary cystatin C as a specific marker of tubular dysfunction
- Time-resolved fluorimetric immunoassay of calprotectin: technical and clinical aspects in diagnosis of inflammatory bowel diseases
- Direct and fast determination of antiretroviral drugs by automated online solid-phase extraction-liquid chromatography-tandem mass spectrometry in human plasma
- Markers of oxidative stress in children with Down syndrome
- Influence of hemolysis on routine clinical chemistry testing
- C-Reactive protein and neopterin levels in healthy non-obese adults
- Comparison of the lipid profile and lipoprotein(a) between sedentary and highly trained subjects
- Clinical outcome estimates based on treatment target limits of laboratory tests: proposal for a plot visualizing effects and differences of medical target setting exemplified by glycemic control in diabetes
- Metrological traceability of values for catalytic concentration of enzymes assigned to a calibration material
- Evaluation of a new Sebia kit for analysis of hemoglobin fractions and variants on the Capillarys® system
- Recommendation for measuring and reporting chloride by ISEs in undiluted serum, plasma or blood: International Federation of Clinical Chemistry and Laboratory Medicine (IFCC): IFCC Scientific Division, Committee on Point of Care Testing and Working Group on Selective Electrodes
- Diluent Multiassay for the MODULAR ANALYTICS E170 does not improve TSH dilutions compared to Diluent Universal
Artikel in diesem Heft
- Recent advances in physiological calcium homeostasis
- Associations of apolipoprotein E exon 4 and lipoprotein lipase S447X polymorphisms with acute ischemic stroke and myocardial infarction
- Association of angiotensin II type 1 receptor gene polymorphism with carotid atherosclerosis
- Comparison of the TaqMan and LightCycler systems in pharmacogenetic testing: evaluation of CYP2C9*2/*3 polymorphisms
- Urinary cystatin C as a specific marker of tubular dysfunction
- Time-resolved fluorimetric immunoassay of calprotectin: technical and clinical aspects in diagnosis of inflammatory bowel diseases
- Direct and fast determination of antiretroviral drugs by automated online solid-phase extraction-liquid chromatography-tandem mass spectrometry in human plasma
- Markers of oxidative stress in children with Down syndrome
- Influence of hemolysis on routine clinical chemistry testing
- C-Reactive protein and neopterin levels in healthy non-obese adults
- Comparison of the lipid profile and lipoprotein(a) between sedentary and highly trained subjects
- Clinical outcome estimates based on treatment target limits of laboratory tests: proposal for a plot visualizing effects and differences of medical target setting exemplified by glycemic control in diabetes
- Metrological traceability of values for catalytic concentration of enzymes assigned to a calibration material
- Evaluation of a new Sebia kit for analysis of hemoglobin fractions and variants on the Capillarys® system
- Recommendation for measuring and reporting chloride by ISEs in undiluted serum, plasma or blood: International Federation of Clinical Chemistry and Laboratory Medicine (IFCC): IFCC Scientific Division, Committee on Point of Care Testing and Working Group on Selective Electrodes
- Diluent Multiassay for the MODULAR ANALYTICS E170 does not improve TSH dilutions compared to Diluent Universal
